Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00401089CT.gov Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Tardive Dyskinesia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Panax Ginseng (this asset) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | P1/2 | CCC · 52 |
| MT-5199 | Neurocrine Biosciences | P4 | BBB |
| Ginkgo Biloba | Beijing HuiLongGuan Hospital | P3 | BB |
| Varenicline | Corporal Michael J. Crescenz VA Medical Center | P4 | B |
| Pyridoxol | Beersheva Mental Health Center | P3 | B |
| Safinamide | Zambon SpA | P3 | B |
| 1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)- | Novartis Pharmaceuticals | P2 | B |
| [14c] lpm3770164 | Luye Pharma Group Ltd. | P1 | CCC |
| Pyridoxal 5'-Phosphate | Medicure | P2 | CCC |
+6 more in the Tardive Dyskinesia cohort
Other indications for Panax Ginseng
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer | — | P1/2 | CCC · 48 |
| Schizoaffective Disorder | — | P1/2 | CCC · 48 |
| Alzheimer Disease | — | P1/2 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Panax Ginseng in Tardive Dyskinesia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/panax-ginseng-tardive-dyskinesia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →